Generate Life Sciences
Generate Life Sciences provides donor sperm and egg banking, newborn stem cell storage, post-birth genetic screening, and ART device distribution through brands like California Cryobank and CBR. It serves 1,200+ IVF clinics and nearly one million families across the U.S., Canada, and Australia under parent CooperSurgical.
- Company typePrivate
- Founded2020
- HeadquartersLos Angeles, United States
- Headcount501–1,000
- GTM typeB2B and B2C
- OfferingServices
What Generate Life Sciences does
Generate Life Sciences is a global life sciences company operating across the family-formation continuum from preconception through post-birth, with brands spanning donor gamete banking (California Cryobank, NW Cryobank, Donor Egg Bank USA), newborn stem cell storage (Cord Blood Registry, Cell Care), post-birth genetic screening (ReadyGen, in partnership with Sema4), and assisted reproductive technology distribution (Kitazato USA, DonorApplication.com). The company reports approximately 50% market share in the premium donor sperm category, 900,000+ newborn stem cell units in storage, 500+ sperm donors and 380+ egg donors, and a roster of 1,200+ IVF clinic customers served annually. Since founding in 1977, the company states it has helped nearly 1 million families and contributed to 75,000+ births.
The core technology stack is built around cryopreservation of reproductive cells (sperm, eggs) and newborn stem cells (cord blood and cord tissue), supplemented by Computer-Assisted Sperm Analysis (CASA) for motility and morphology evaluation. Cord Blood Registry pioneered cord tissue storage in 2010 for mesenchymal stem cells used in regenerative medicine applications, and 12 licensed genetic counselors support clinical interpretation services. Generate also serves as the exclusive U.S. distributor of Kitazato vitrification devices and related ART consumables, distributing into 40+ countries. Operations span eight U.S. locations (Los Angeles, Tucson, New York, Boston, Palo Alto, Rockville, among others) with international sites in Australia and Canada via the 2021 Cell Care Group acquisition, supported by 500+ employees.
The business model blends direct-to-consumer sales (donor sperm and eggs to individuals, cord blood and cord tissue storage to expectant families) with B2B distribution to fertility clinics and embryology laboratories. Revenue is generated through transaction fees on donor gametes and vitrification devices, and recurring subscription revenue from long-term newborn stem cell storage contracts renewed annually. All tissue banking operations are FDA-registered and AATB-accredited, with state licensure in California, New York, Illinois, and Maryland. Generate has operated as a wholly-owned subsidiary of CooperSurgical (CooperCompanies, NYSE: COO) since 2021.
Generate Life Sciences firmographics
Firmographics- Name
- Generate Life Sciences
- Legal name
- Generate Life Sciences Co.
- Website
- https://generate.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Acquired
- Headcount range
- 501–1,000 employees
- Short description
- Generate Life Sciences provides donor sperm and egg banking, newborn stem cell storage, post-birth genetic screening, and ART device distribution through brands like California Cryobank and CBR. It serves 1,200+ IVF clinics and nearly one million families across the U.S., Canada, and Australia under parent CooperSurgical.
- Ownership category
- akta.pro rank
Generate Life Sciences industry classification
Industry- Product category
- Reproductive and Cryobank Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)
- akta.pro secondary industries
- Genetic & Prenatal Testing Laboratories (HLAFAMAH), Stem Cell–Based Regenerative Therapies (HLAAAGAA), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
Keywords
Where Generate Life Sciences is headquartered
LocationHeadquarters
- HQ city
- Los Angeles
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
Generate Life Sciences business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Reproductive Services (Donor Sperm & Egg): Sales of donor sperm and donor eggs to individuals and couples. California Cryobank holds 50% market share in premium donor sperm market. One of the largest reproductive services companies globally with 500+ sperm donors and 380+ egg donors.
- Newborn Stem Cell Storage: Cord blood and tissue collection, processing, and storage services. 900K+ newborn stem cell units stored. Storage renewal accounts available online or over the phone.
- Medical Device Distribution: Exclusive U.S. Distributor of Kitazato vitrification devices for IVF clinics.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels4 records
Generate Life Sciences product offering
Product offeringCore offering
Generate Life Sciences is a global life sciences company that provides reproductive, newborn stem cell, and genetic services. Its core offerings include frozen donor sperm and egg banking through California Cryobank and Donor Egg Bank USA, cord blood and tissue storage through CBR, post-birth genetic screening via ReadyGen, and exclusive U.S. distribution of Kitazato vitrification devices to IVF clinics.
Product overview
Generate Life Sciences operates as a comprehensive life sciences platform offering reproductive, newborn stem cell, and genetic services. The company provides a unified portfolio consisting of California Cryobank (sperm and egg banking with 50% premium market share), CBR (largest U.S. newborn stem cell bank with 900K+ units), Donor Egg Bank USA, NW Cryobank, FamilyCord, Kitazato USA (vitrification device distribution), Donor Application, and ReadyGen. Services span from preconception (donor sperm/eggs, fertility preservation) through birth (cord blood/tissue banking) to post-birth (genetic screening). The company serves 1,200+ IVF clinics annually and has helped nearly 1 million families.
Differentiator
Problem solved
Functional benefit
Brands
- California Cryobank: Premier sperm and egg bank, one of the largest reproductive services companies globally with 50% market share in premium donor sperm market
- CBR (Cord Blood Registry)
- Donor Egg Bank USA
- NW Cryobank
- Kitazato USA
- Donor Application
- ReadyGen
Products and services
- California Cryobank
- CBR (Cord Blood Registry)
- Donor Egg Bank USA
- NW Cryobank
- Kitazato USA
- Donor Application
- ReadyGen
Quantifiable outcome
- 50% market share in premium donor sperm market
- +3 more outcomes
Companies that use Generate Life Sciences
Customer profileNamed customers2 records
Segments5 records
Ideal customer profiles3 records
Generate Life Sciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature3 records
Generate Life Sciences partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core, flagship and minor.
- Cell Care Group (Australia)coreGenerate Life Sciences acquired Cell Care international cord blood banking group, comprising Cell Care in Australia, Insception Lifebank and Cells for Life in Canada, and Victoria Angel public bank. Expands operational footprint to three countries and adds 200,000+ cord blood and tissue samples.
- CooperSurgical (CooperCompanies)flagshipCooperSurgical, a recognized global leader in women's health and fertility solutions, completed acquisition of Generate Life Sciences. CooperSurgical is part of CooperCompanies (NYSE: COO). Announcement of acquisition made in 2021 with completion confirmed on the Generate website.
- NantKwestminorCord Blood Registry (CBR) partnered with NantKwest to develop COVID-19 treatment using newborn stem cells. CBR established a biorepository for investigational studies in acute and persistent COVID-19.
- Sema4coreGenerate launched ReadyGen post-birth genetic services in partnership with Sema4, expanding genetic screening offerings to families.
- KitazatocoreCalifornia Cryobank entered the medical device space with an exclusive distribution deal with Kitazato, becoming exclusive U.S. Distributor of the world's leading vitrification devices.
Scale indicators17 records
Recent moves7 records
Expansion highlights5 records
Generate Life Sciences competitors and assessment
Company assessmentDirect peers
- Fairfax Cryobank: Major U.S. donor sperm bank and fertility tissue repository that competes head-to-head with California Cryobank for premium gamete sales to IVF clinics and individuals.
- Xytex: Donor sperm bank with a large international catalog, competing with California Cryobank in premium and identity-release donor segments.
- ViaCord: Cord blood and cord tissue banking service (Revvity/PerkinElmer) that competes directly with CBR for newborn stem cell storage enrollments.
- Cryos International: Global sperm and egg bank headquartered in Denmark, competing with California Cryobank for cross-border donor gamete shipments and IVF clinic distribution.
- Cryo-Cell International: One of the largest U.S. cord blood banking companies and a direct competitor to Generate's CBR business, also offering menstrual blood and other cellular storage services to families.
Emerging players
- TMRW Life Sciences: Technology-focused cryostorage platform for reproductive cells (IVF specimens) that could disintermediate traditional banks by offering automated, software-managed storage infrastructure.
Broad incumbents
- Genea Biomedx: Developer of IVF lab instruments and consumables (incubators, vitrification tools) competing in the same clinic-procurement channel where Generate's Kitazato line is sold.
- CooperSurgical: Generate's parent company and a global women's-health and fertility medical-device platform; pre-acquisition overlap in IVF consumables and devices made CooperSurgical both a partner and a comparable broad incumbent in the fertility ecosystem.
- Vitrolife: Global IVF media, consumables, and time-lapse incubator provider whose vitrification and culture media overlap with Kitazato USA's device business distributed by Generate.
Regional players
- European Sperm Bank: Denmark-based donor sperm bank focused on European and select international markets, comparable in catalog breadth and clinic distribution model but not directly overlapping in the U.S.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Generate Life Sciences social profiles
Digital presenceGenerate Life Sciences compliance and trust
Trust signalCompliance6 records
Generate Life Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Generate Life Sciences leadership team
Management profileNumber of profiles
Profiles7 records
Generate Life Sciences subsidiaries and ownership
Company hierarchySubsidiaries10 records
Generate Life Sciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Generate Life Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Generate Life Sciences
What does Generate Life Sciences do?
Generate Life Sciences is a global life sciences company that provides reproductive, newborn stem cell, and genetic services. Its core offerings include frozen donor sperm and egg banking through California Cryobank and Donor Egg Bank USA, cord blood and tissue storage through CBR, post-birth genetic screening via ReadyGen, and exclusive U.S. distribution of Kitazato vitrification devices to IVF clinics.
Is Generate Life Sciences a public or private company?
Generate Life Sciences is a private company. It is classified as corporate owned and is currently acquired.
When was Generate Life Sciences founded?
Generate Life Sciences was founded in 2020. It employs 501 to 1,000 people.
Where is Generate Life Sciences based?
Generate Life Sciences is headquartered in Los Angeles, United States, in the North America region.
How does Generate Life Sciences make money?
Three revenue lines are on record. Reproductive Services (Donor Sperm & Egg) is the primary driver. The others are newborn Stem Cell Storage and medical Device Distribution.
Who are Generate Life Sciences's main competitors?
Direct peers on record are Fairfax Cryobank, Xytex, ViaCord, Cryos International and Cryo-Cell International. TMRW Life Sciences is listed as an emerging player. Broad incumbents are Genea Biomedx, CooperSurgical and Vitrolife. European Sperm Bank is listed as a regional player.
Does Generate Life Sciences have an API?
No public API is recorded for Generate Life Sciences.
What industry is Generate Life Sciences in?
Generate Life Sciences's product category is Reproductive and Cryobank Services. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening), with a secondary code of HLAFAMAH, Genetic & Prenatal Testing Laboratories. Its NAICS code is 541714 and its SIC code is 2835.